The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

about

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.

P2860

Q35742023-D724459B-2FEE-4E72-86D3-A125D325F31F Q38684505-BD1C2B8E-6319-4B1F-80D4-7575C2A1F164

P2860

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

Item

http://www.wikidata.org/entity/Q36779141

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@ast

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@en

type

Item

label

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@ast

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@en

prefLabel

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@ast

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@en

P1476

The effects of febuxostat on t ...... glitazone, a CYP2C8 substrate.

@en

P2093

Himanshu Naik

http://www.w3.org/2001/XMLSchema#string

Jing-Tao Wu

http://www.w3.org/2001/XMLSchema#string

Lachy McLean

http://www.w3.org/2001/XMLSchema#string

Robert Palmer

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Pathogenesis of Gout

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

P304

327-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2012.04182.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221745522

http://www.w3.org/2001/XMLSchema#string

P698

22242967

http://www.w3.org/2001/XMLSchema#string

P932

3630752

http://www.w3.org/2001/XMLSchema#string

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

about

P2860

P2860

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932